Roche Aktie - RHO

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Current Price

296,40

( 0,07% )

Gebot

297,00

Fragen

297,20

Volumen

294

295,20 Tagesbereich 299,20

281,00 52-Wochen-Bereich 316,20

Marktkapitalisierung

237,292B

Handelsende

296,20

Handelsbeginn

295,80

Letzte Trade

296.39999

Letzter Handelszeitpunkt

13:25:39

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

626

Ausgegebene Aktien

800.578.845

Dividendenrendite

Kurs-Gewinn-Verhältnis

0,00

Gewinn pro Aktie (EPS)

Erlöse

60,5B

Nettogewinn

8,28B

Sektor

Pharmaceutical Preparations

Branche

Pharmaceutical Preparations

Website

www.roche.com

Hauptsitz

Basel, Che

Gegründet

Roche Holding AG is listed in the Pharmaceutical Preparations sector of the Tradegate (DE) with ticker RHO. The last closing price for Roche was 296,20 €. Over the last year, Roche shares have traded in a share price range of 281,00 € to 316,20 €.

Roche currently has 800.578.845 shares in issue. The market capitalisation of Roche is 237,13 € billion.

Changes to the Roche Enlarged Corporate Executive Committee

Changes to the Roche Enlarged Corporate Executive Committee Basel, 30 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Johannes...

Early data suggest Roche’s NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A

Early data suggest Roche’s NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A Positive phase I/II...

Roche’s Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma

Roche’s Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma Pivotal...

Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease

Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease Results from Phase IIb PADOVA and longer term...

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in...

Roche’s Evrysdi tablet approved by European Commission as first and only for Spinal Muscular Atrophy (SMA)

Roche’s Evrysdi tablet approved by European Commission as first and only for Spinal Muscular Atrophy (SMA) Simplified storage and administration...

Roche’s Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer

Roche’s Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer 46% reduction in the...

New data show Roche’s Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer

New data show Roche’s Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer The ItovebiTM...

Roche’s fenebrutinib maintains near-complete suppression of disease activity and disability progression for up to two years in people with relapsing multiple sclerosis

Roche’s fenebrutinib maintains near-complete suppression of disease activity and disability progression for up to two years in people with...

CHMP recommends EU approval of Roche’s Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer

CHMP recommends EU approval of Roche’s Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer Positive recommendation...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0.79999	0.270632611637	295.6	299.8	288.6	651	293.72774194	DE
4	-9	-2.94695490985	305.39999	309.8	287.2	577	296.36043401	DE
12	-6.60001	-2.17822112211	303	316.2	281	626	298.81234971	DE
26	-6.60001	-2.17822112211	303	316.2	281	626	298.81234971	DE
52	-6.60001	-2.17822112211	303	316.2	281	626	298.81234971	DE
156	-6.60001	-2.17822112211	303	316.2	281	626	298.81234971	DE
260	46.39999	18.559996	250	316.2	250	613	298.81234971	DE

RHO - Frequently Asked Questions (FAQ)

What is the current Roche share price?

The current share price of Roche is 296,40 €

How many Roche shares are in issue?

Roche has 800.578.845 shares in issue

What is the market cap of Roche?

The market capitalisation of Roche is EUR 237,13B

What is the 1 year trading range for Roche share price?

Roche has traded in the range of 281,00 € to 316,20 € during the past year

What is the reporting currency for Roche?

Roche reports financial results in CHF

What is the latest annual turnover for Roche?

The latest annual turnover of Roche is CHF 60,5B

What is the latest annual profit for Roche?

The latest annual profit of Roche is CHF 8,28B

What is the registered address of Roche?

The registered address for Roche is GRENZACHERSTRASSE 124, BASEL, 4070

What is the Roche website address?

The website address for Roche is www.roche.com

Which industry sector does Roche operate in?

Roche operates in the PHARMACEUTICAL PREPARATIONS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
50C0BIT Mining Ltd	7,65 € (264,29%)	15,86k
KU9WK Kellogg Co	22,89 € (53,11%)	32,63k
IGS1IGC Pharma Inc	0,462 € (47,13%)	7,24k
L7C2Windfall Geotek Inc	0,0115 € (43,75%)	10,88k
YH1Air Industries Group	3,94 € (39,72%)	270
MAH0Mereo Biopharma Group Plc	1,62 € (-35,20%)	20,4k
EUSKore Mining Ltd	0,0095 € (-34,48%)	1,3k
2DV0Drone Volt	0,878 € (-30,65%)	376,8k
7BC0Forte Group Holdings Inc	0,091 € (-26,61%)	1,13k
UP0Ultragenyx Pharmaceutical Inc	27,40 € (-22,60%)	376
ABBVolatus Aerospace Inc	0,484 € (26,04%)	16,8M
N04NuCana plc	0,065 € (22,64%)	12,6M
D7GNel ASA	0,2438 € (3,04%)	4,3M
4BHClara Technologies Corp	7,75 € (-20,10%)	3,73M
DRHDroneShield Limited	1,476 € (2,50%)	1,46M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Roche Holding AG (RHO)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über Roche Holding AG

RHO Neueste Nachrichten

Changes to the Roche Enlarged Corporate Executive Committee

Early data suggest Roche’s NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A

Roche’s Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma

Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients

Roche’s Evrysdi tablet approved by European Commission as first and only for Spinal Muscular Atrophy (SMA)

Roche’s Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer

New data show Roche’s Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer

Roche’s fenebrutinib maintains near-complete suppression of disease activity and disability progression for up to two years in people with relapsing multiple sclerosis

CHMP recommends EU approval of Roche’s Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer

RHO - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Roche Holding AG (RHO) Börsenkurse

Roche Holding AG (RHO)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über Roche Holding AG

RHO Neueste Nachrichten

Changes to the Roche Enlarged Corporate Executive Committee

Early data suggest Roche’s NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A

Roche’s Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma

Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients

Roche’s Evrysdi tablet approved by European Commission as first and only for Spinal Muscular Atrophy (SMA)

Roche’s Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer

New data show Roche’s Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer

Roche’s fenebrutinib maintains near-complete suppression of disease activity and disability progression for up to two years in people with relapsing multiple sclerosis

CHMP recommends EU approval of Roche’s Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer

RHO - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Anmelden

Werbung entfernen